F
Francesca Pastorelli
Researcher at University of Bologna
Publications - 30
Citations - 1830
Francesca Pastorelli is an academic researcher from University of Bologna. The author has contributed to research in topics: Amyloidosis & Transthyretin. The author has an hindex of 13, co-authored 29 publications receiving 1556 citations.
Papers
More filters
Journal ArticleDOI
Systemic Cardiac Amyloidoses Disease Profiles and Clinical Courses of the 3 Main Types
Claudio Rapezzi,Giampaolo Merlini,Candida Cristina Quarta,Letizia Riva,Simone Longhi,Ornella Leone,Fabrizio Salvi,Paolo Ciliberti,Francesca Pastorelli,Elena Biagini,Fabio Coccolo,Robin M. T. Cooke,Letizia Bacchi-Reggiani,Diego Sangiorgi,Alessandra Ferlini,Michele Cavo,Elena Zamagni,Maria Luisa Fonte,Giovanni Palladini,Francesco Salinaro,Francesco Musca,Laura Obici,Angelo Branzi,Stefano Perlini +23 more
TL;DR: AL, ATTRm, and ATTRwt should be considered 3 different cardiac diseases, probably characterized by different pathophysiological substrates and courses.
Journal ArticleDOI
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings
Guido Cavaletti,David R. Cornblath,Ingemar S. J. Merkies,Tjeerd J. Postma,Emanuela Rossi,Barbara Frigeni,Paola Alberti,Jordi Bruna,Roser Velasco,Andreas A. Argyriou,Haralabos P. Kalofonos,Dimitri Psimaras,Damien Ricard,Andrea Pace,Edvina Galiè,Chiara Briani,C. Dalla Torre,Catharina G. Faber,Roy I. Lalisang,W. Boogerd,W. Boogerd,Dieta Brandsma,Susanne Koeppen,Jörg Hense,Dawn J Storey,S. Kerrigan,Angelo Schenone,Sabrina Fabbri,Maria Grazia Valsecchi,Anna Mazzeo,Antonio Toscano,Brigitte A. Brouwer,B. Piras,C. Dominguez gonzalez,Chiara Tomasello,D. Binda,D. Cortinovis,E. Lindeck pozza,Els K. Vanhoutte,Francesca Lanzani,Francesca Pastorelli,Giuseppe Altavilla,Giuseppe Granata,I. Ghignotti,J. Heimans,Laura Mattavelli,Luca Padua,L. Reni,Mayienne Bakkers,Marta Campagnolo,M.E. Cazzaniga,M. Eurelings,Massimo Leandri,Marta Lucchetta,M. Penas prado,M. Russo,M Piatti,P. Bidoli,Robin Grant,R. Plasmati,R. J. Meijer,Susan G. Dorsey,Stefania Galimberti,Wolfgang Grisold,A. Pessino +64 more
TL;DR: Good validity and reliability scores were demonstrated for the set of selected impairment and quality-of-life outcome measures in CIPN and future studies are planned to investigate the responsiveness aspects of these measures.
Journal ArticleDOI
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale.
Guido Cavaletti,Barbara Frigeni,Francesca Lanzani,M Piatti,Stefania Rota,Chiara Briani,Gabriella Zara,R. Plasmati,Francesca Pastorelli,Augusto Caraceni,Andrea Pace,Mariagrazia Manicone,Andrea Lissoni,Nicoletta Colombo,Giulia Bianchi,Claudio Zanna +15 more
TL;DR: The TNSc is proposed as a reliable method for assessing not only the severity but also the changes in CIPN, confirming the results of previous studies.
Journal ArticleDOI
Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
R. Plasmati,Francesca Pastorelli,Michele Cavo,Elisabetta Petracci,Elena Zamagni,Patrizia Tosi,Delia Cangini,Paola Tacchetti,Flavia Salvi,Ilaria Bartolomei,Roberto Michelucci,Carlo Alberto Tassinari +11 more
TL;DR: Peripheral neuropathy, sometimes subclinical, and mild in patients, is a common, early side effect of thalidomide therapy, and the high doses used in all patients for a relatively short time (4 months) rule out any correlations between Neuropathy, total dose, and duration of treatment.
Journal ArticleDOI
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
Patrizia Tosi,Elena Zamagni,Claudia Cellini,R. Plasmati,Delia Cangini,Paola Tacchetti,Giulia Perrone,Francesca Pastorelli,Sante Tura,Michele Baccarani,Michele Cavo +10 more
TL;DR: The results suggest that long‐term thalidomide therapy in MM may be hampered by the remarkable neurotoxicity of the drug, and that a neurological evaluation should be mandatory prior to thalidmide treatment, in order to identify patients at risk of developing a peripheral neuropathy.